内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetes Obes Metab：CC趋化因子受体拮抗剂有助于控制血糖

2014-05-20 伊文 中华医学会糖尿病学分会

趋化因子受体拮抗剂控制血糖
关注

既往研究提示，巨噬细胞通过C-C基序趋化因子受体2（CCR2）在脂肪组织中浸润可能参与胰岛素抵抗和2型糖尿病的发生过程。一项为期4周的随机、双盲、安慰剂对照、多中心研究表明，CCR2拮抗剂JNJ-41443532（口服，250 mg，每日两次）对2型糖尿病患者有中度血糖改善作用，对胰岛素抵抗的改善作用不如吡格列酮，但对β细胞功能有显著改善作用。此外，JNJ-41443532耐受性良好，治疗期间未发

既往研究提示，巨噬细胞通过C-C基序趋化因子受体2（CCR2）在脂肪组织中浸润可能参与胰岛素抵抗和2型糖尿病的发生过程。一项为期4周的随机、双盲、安慰剂对照、多中心研究表明，CCR2拮抗剂JNJ-41443532（口服，250 mg，每日两次）对2型糖尿病患者有中度血糖改善作用，对胰岛素抵抗的改善作用不如吡格列酮，但对β细胞功能有显著改善作用。此外，JNJ-41443532耐受性良好，治疗期间未发生严重不良事件。







原始出处：

Di Prospero NA1, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L, Rothenberg P.CCR2 antagonism in patients with type-2 diabetes mellitus: A randomized, placebo-controlled study.Diabetes Obes Metab. 2014 May 2. doi: 10.1111/dom.12309. [Epub ahead of print]【原文下载】

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2014-07-28 智智灵药

    #BET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2014-09-12 ms9608593228839890

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2015-04-11 x35042875

    国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2014-07-19 一闲

    #MET#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2015-04-11 guojianrong

    #Meta#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2015-05-03 木头人513

    #Diabetes#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2014-07-21 s_pl2008

    #控制血糖#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2015-02-22 一叶知秋

    #CC趋化因子#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2014-05-22 ms5236388012055669

    #拮抗剂#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1759447, encodeId=4e9d1e594471a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 28 13:52:00 CST 2014, time=2014-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636869, encodeId=796716368693d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 12 21:52:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20835, encodeId=801f2083512, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:51:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895726, encodeId=2c511895e260a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 19 09:52:00 CST 2014, time=2014-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887389, encodeId=3780188e3894d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Apr 11 06:52:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901211, encodeId=8e831901211b3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun May 03 21:52:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934531, encodeId=6e761934531f9, content=<a href='/topic/show?id=b65a56e400e' target=_blank style='color:#2F92EE;'>#控制血糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56740, encryptionId=b65a56e400e, topicName=控制血糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Mon Jul 21 04:52:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782679, encodeId=fc361e82679f0, content=<a href='/topic/show?id=9d8b425172' target=_blank style='color:#2F92EE;'>#CC趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4251, encryptionId=9d8b425172, topicName=CC趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Feb 22 09:52:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511620, encodeId=b6ca1511620ca, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553394, encodeId=6a301553394c2, content=<a href='/topic/show?id=553a9296e09' target=_blank style='color:#2F92EE;'>#趋化因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92967, encryptionId=553a9296e09, topicName=趋化因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e70614370473, createdName=shijzhiewnjhch, createdTime=Thu May 22 05:52:00 CST 2014, time=2014-05-22, status=1, ipAttribution=)]
    2014-05-22 shijzhiewnjhch

    #趋化因子#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Science：抗HIV药物阻断病毒入侵分子机制被揭示

　　 　　 9月12日，美国《科学》杂志-美国科学促进会（Science-AAAS）在中国科学院上海药物研究所召开新闻发布会，介绍中科院上海药物研究所吴蓓丽研究员研究组在趋化因子受体CCR5结构生物学领域取得重大突破性进展。相关研究成果发表在《科学》（Science）上，吴蓓丽研究员为唯一通讯作者，上海药物研究所为第一作者单位。这也是《科学》杂志-美国科学促进会第一次在上海召开的新